Global healthcare company Penumbra has reported positive data from the INSIGHT Registry for its RED reperfusion catheters as well as the sub-analyses of the COMPLETE study for its Penumbra System.
In the INSIGHT Registry, the company’s new RED reperfusion catheters were evaluated in 161 acute ischemic stroke (AIS) patients.
The RED reperfusion catheters (RED 72, RED 68 and RED 62) were designed for use in the revascularisation of AIS patients.
The initial data from INSIGHT Registry showed that the catheters were successful in removing all clot types. In these patients, 68.9% had successful first-pass revascularisation (mTICI≥2b-3) and 97% had successful revascularisation following the final angiogram.
Penumbra interventional president Sandra Lesenfants said: “The initial data from our Insight Registry is very promising. With such a high first pass rate, Penumbra’s RED catheters can restore blood flow much quicker, which we know can lead to improved outcomes for patients.
“Penumbra’s focus has always been to help as many people as we can, and this data demonstrates that our latest technology is indeed making a positive impact.”
The data from the sub-analyses of the prospective, multicentre, post-market, global COMPLETE study demonstrated that the Penumbra System is effective for treating AIS patients with tandem lesions as well as patients considered in the late stage of treatment.
The findings showed that patients with anterior circulation tandem lesions with stenosis higher than 50% treated with the Penumbra System had successful revascularisation, with 89% achieving mTICI 2b-3 and about 64% achieving 90-day mRS 0-2.
The patients in the late window had successful revascularisation using the Penumbra System in 83.2% of the cases.
In April, Penumbra’s Indigo Aspiration System with Lightning 7 and Lightning 12 mechanical thrombectomy technologies received CE Mark.